Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Daiichi Sankyo

Thumbnail
March 24, 2021

Aptose adds 60% on lead asset rebrand

Thumbnail
January 28, 2021

Zymeworks investors wake up to competition

With mounting competition in Her2-directed breast cancer treatment, Zymeworks’ latecomer struggles to show that it’s better.

Article image
Vantage logo
January 18, 2021

Asco-GI 2021 round-up – Cardiff disappoints while Arcus intrigues

Article image
Vantage logo
December 17, 2020

Macrogenics gets to market, but what comes next?

Article image
Vantage logo
November 27, 2020

Go or no go? The year ends with Covid-19 vaccine approvals in sight

December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.

Article image
Vantage logo
November 25, 2020

Bergenbio dream lives on, despite Genmab's broken Axl

Genmab cans its antibody-drug conjugate against Axl kinase, an approach on which Bergenbio has gone all in.

Article image
Vantage logo
November 11, 2020

Five Prime looks to turn a corner

Survival data with bemarituzumab see the company erase half of the past three years’ losses.

Article image
Vantage logo
October 02, 2020

Amag buyers bet big on reversal agent

Article image
Vantage logo
September 15, 2020

Seattle benefits from Merck's long shot

Merck's move on a target that has attracted little attention – Liv-1 – means future data readouts are now eagerly awaited.

Article image
Vantage logo
August 07, 2020

Biogen pays $560m for an unproven Parkinson’s mechanism

All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.

Article image
Vantage logo
July 27, 2020

Another Astra-Daiichi tie-up puts Trop2 in focus

The UK big pharma is set to hand Japan’s Daiichi $1bn for rights to a second antibody-drug conjugate. Immunomedics watch out.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
March 22, 2021

AACR 2021 preview – the early themes emerge

Vantage logo
March 24, 2021

Big pharma’s key catalysts in the second quarter

Vantage logo
March 03, 2021

A busy year ahead for Parkinson’s disease

Vantage logo
March 23, 2021

Frequency refuses to hear the death knell

Vantage logo
February 18, 2021

The reckoning begins for biotech-focused Spacs

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.